世界の転移性抗がん剤市場インサイト及び予測(トラスツズマブ、ペルツズマブ)

◆英語タイトル:Global Metastatic Cancer Drug Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX09253)◆商品コード:QY22JLX09253
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:115
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、転移性抗がん剤のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に転移性抗がん剤の世界市場のxxx%を占める「トラスツズマブ」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
転移性抗がん剤の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの転移性抗がん剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

転移性抗がん剤のグローバル主要企業には、AstraZeneca、Merck、Pfizer、Celgene、AKRON、Novartis、Galen、Pacira BioSciences、Johnson & Johnson、Fresenius Kabi AG、Spectrum Pharmaceuticals、Takeda Pharmaceutical、Teva Pharmaceutical Industries、Cipla、Sun Pharmaceutical Industries、Shanghai Fosun Pharmaceutical、Ingenusなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

転移性抗がん剤市場は、種類と用途によって区分されます。世界の転移性抗がん剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
トラスツズマブ、ペルツズマブ

【用途別セグメント】
病院、専門クリニック

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 転移性抗がん剤製品概要
- 種類別市場(トラスツズマブ、ペルツズマブ)
- 用途別市場(病院、専門クリニック)
- 調査の目的
・エグゼクティブサマリー
- 世界の転移性抗がん剤販売量予測2017-2028
- 世界の転移性抗がん剤売上予測2017-2028
- 転移性抗がん剤の地域別販売量
- 転移性抗がん剤の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別転移性抗がん剤販売量
- 主要メーカー別転移性抗がん剤売上
- 主要メーカー別転移性抗がん剤価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(トラスツズマブ、ペルツズマブ)
- 転移性抗がん剤の種類別販売量
- 転移性抗がん剤の種類別売上
- 転移性抗がん剤の種類別価格
・用途別市場規模(病院、専門クリニック)
- 転移性抗がん剤の用途別販売量
- 転移性抗がん剤の用途別売上
- 転移性抗がん剤の用途別価格
・北米市場
- 北米の転移性抗がん剤市場規模(種類別、用途別)
- 主要国別の転移性抗がん剤市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの転移性抗がん剤市場規模(種類別、用途別)
- 主要国別の転移性抗がん剤市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の転移性抗がん剤市場規模(種類別、用途別)
- 主要国別の転移性抗がん剤市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の転移性抗がん剤市場規模(種類別、用途別)
- 主要国別の転移性抗がん剤市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの転移性抗がん剤市場規模(種類別、用途別)
- 主要国別の転移性抗がん剤市場規模(トルコ、サウジアラビア)
・企業情報
AstraZeneca、Merck、Pfizer、Celgene、AKRON、Novartis、Galen、Pacira BioSciences、Johnson & Johnson、Fresenius Kabi AG、Spectrum Pharmaceuticals、Takeda Pharmaceutical、Teva Pharmaceutical Industries、Cipla、Sun Pharmaceutical Industries、Shanghai Fosun Pharmaceutical、Ingenus
・産業チェーン及び販売チャネル分析
- 転移性抗がん剤の産業チェーン分析
- 転移性抗がん剤の原材料
- 転移性抗がん剤の生産プロセス
- 転移性抗がん剤の販売及びマーケティング
- 転移性抗がん剤の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 転移性抗がん剤の産業動向
- 転移性抗がん剤のマーケットドライバー
- 転移性抗がん剤の課題
- 転移性抗がん剤の阻害要因
・主な調査結果

Metastatic cancer (also referred as advanced or stage 4 cancer) occurs when the primary cancer has spread to other parts of the body via the lymphatic or blood circulation systems. Although it can spread to almost every organ in the body, some cancers, such as breast cancer, can spread to the lungs, liver, bones, and brain.The metastatic cancer drug is supportive and aims to reduce the severity of the symptoms.
Market Analysis and Insights: Global Metastatic Cancer Drug Market
The global Metastatic Cancer Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Trastuzumab accounting for % of the Metastatic Cancer Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Metastatic Cancer Drug market size is valued at US$ million in 2021, while the North America and Europe Metastatic Cancer Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Metastatic Cancer Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metastatic Cancer Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metastatic Cancer Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metastatic Cancer Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metastatic Cancer Drug market.
Global Metastatic Cancer Drug Scope and Market Size
Metastatic Cancer Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Metastatic Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Trastuzumab
Pertuzumab
Segment by Application
Hospitals
Specialty Clinics
By Company
AstraZeneca
Merck
Pfizer
Celgene
AKRON
Novartis
Galen
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi AG
Spectrum Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Cancer Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Trastuzumab
1.2.3 Pertuzumab
1.3 Market by Application
1.3.1 Global Metastatic Cancer Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metastatic Cancer Drug Market Perspective (2017-2028)
2.2 Metastatic Cancer Drug Growth Trends by Region
2.2.1 Metastatic Cancer Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metastatic Cancer Drug Historic Market Size by Region (2017-2022)
2.2.3 Metastatic Cancer Drug Forecasted Market Size by Region (2023-2028)
2.3 Metastatic Cancer Drug Market Dynamics
2.3.1 Metastatic Cancer Drug Industry Trends
2.3.2 Metastatic Cancer Drug Market Drivers
2.3.3 Metastatic Cancer Drug Market Challenges
2.3.4 Metastatic Cancer Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metastatic Cancer Drug Players by Revenue
3.1.1 Global Top Metastatic Cancer Drug Players by Revenue (2017-2022)
3.1.2 Global Metastatic Cancer Drug Revenue Market Share by Players (2017-2022)
3.2 Global Metastatic Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metastatic Cancer Drug Revenue
3.4 Global Metastatic Cancer Drug Market Concentration Ratio
3.4.1 Global Metastatic Cancer Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Cancer Drug Revenue in 2021
3.5 Metastatic Cancer Drug Key Players Head office and Area Served
3.6 Key Players Metastatic Cancer Drug Product Solution and Service
3.7 Date of Enter into Metastatic Cancer Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metastatic Cancer Drug Breakdown Data by Type
4.1 Global Metastatic Cancer Drug Historic Market Size by Type (2017-2022)
4.2 Global Metastatic Cancer Drug Forecasted Market Size by Type (2023-2028)
5 Metastatic Cancer Drug Breakdown Data by Application
5.1 Global Metastatic Cancer Drug Historic Market Size by Application (2017-2022)
5.2 Global Metastatic Cancer Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metastatic Cancer Drug Market Size (2017-2028)
6.2 North America Metastatic Cancer Drug Market Size by Type
6.2.1 North America Metastatic Cancer Drug Market Size by Type (2017-2022)
6.2.2 North America Metastatic Cancer Drug Market Size by Type (2023-2028)
6.2.3 North America Metastatic Cancer Drug Market Share by Type (2017-2028)
6.3 North America Metastatic Cancer Drug Market Size by Application
6.3.1 North America Metastatic Cancer Drug Market Size by Application (2017-2022)
6.3.2 North America Metastatic Cancer Drug Market Size by Application (2023-2028)
6.3.3 North America Metastatic Cancer Drug Market Share by Application (2017-2028)
6.4 North America Metastatic Cancer Drug Market Size by Country
6.4.1 North America Metastatic Cancer Drug Market Size by Country (2017-2022)
6.4.2 North America Metastatic Cancer Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Metastatic Cancer Drug Market Size (2017-2028)
7.2 Europe Metastatic Cancer Drug Market Size by Type
7.2.1 Europe Metastatic Cancer Drug Market Size by Type (2017-2022)
7.2.2 Europe Metastatic Cancer Drug Market Size by Type (2023-2028)
7.2.3 Europe Metastatic Cancer Drug Market Share by Type (2017-2028)
7.3 Europe Metastatic Cancer Drug Market Size by Application
7.3.1 Europe Metastatic Cancer Drug Market Size by Application (2017-2022)
7.3.2 Europe Metastatic Cancer Drug Market Size by Application (2023-2028)
7.3.3 Europe Metastatic Cancer Drug Market Share by Application (2017-2028)
7.4 Europe Metastatic Cancer Drug Market Size by Country
7.4.1 Europe Metastatic Cancer Drug Market Size by Country (2017-2022)
7.4.2 Europe Metastatic Cancer Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metastatic Cancer Drug Market Size (2017-2028)
8.2 Asia-Pacific Metastatic Cancer Drug Market Size by Type
8.2.1 Asia-Pacific Metastatic Cancer Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Metastatic Cancer Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Metastatic Cancer Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Metastatic Cancer Drug Market Size by Application
8.3.1 Asia-Pacific Metastatic Cancer Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Metastatic Cancer Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Metastatic Cancer Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Metastatic Cancer Drug Market Size by Region
8.4.1 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Metastatic Cancer Drug Market Size (2017-2028)
9.2 Latin America Metastatic Cancer Drug Market Size by Type
9.2.1 Latin America Metastatic Cancer Drug Market Size by Type (2017-2022)
9.2.2 Latin America Metastatic Cancer Drug Market Size by Type (2023-2028)
9.2.3 Latin America Metastatic Cancer Drug Market Share by Type (2017-2028)
9.3 Latin America Metastatic Cancer Drug Market Size by Application
9.3.1 Latin America Metastatic Cancer Drug Market Size by Application (2017-2022)
9.3.2 Latin America Metastatic Cancer Drug Market Size by Application (2023-2028)
9.3.3 Latin America Metastatic Cancer Drug Market Share by Application (2017-2028)
9.4 Latin America Metastatic Cancer Drug Market Size by Country
9.4.1 Latin America Metastatic Cancer Drug Market Size by Country (2017-2022)
9.4.2 Latin America Metastatic Cancer Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metastatic Cancer Drug Market Size (2017-2028)
10.2 Middle East & Africa Metastatic Cancer Drug Market Size by Type
10.2.1 Middle East & Africa Metastatic Cancer Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Metastatic Cancer Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Metastatic Cancer Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Metastatic Cancer Drug Market Size by Application
10.3.1 Middle East & Africa Metastatic Cancer Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Metastatic Cancer Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Metastatic Cancer Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Metastatic Cancer Drug Market Size by Country
10.4.1 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Metastatic Cancer Drug Introduction
11.1.4 AstraZeneca Revenue in Metastatic Cancer Drug Business (2017-2022)
11.1.5 AstraZeneca Recent Developments
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Metastatic Cancer Drug Introduction
11.2.4 Merck Revenue in Metastatic Cancer Drug Business (2017-2022)
11.2.5 Merck Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Metastatic Cancer Drug Introduction
11.3.4 Pfizer Revenue in Metastatic Cancer Drug Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 Celgene
11.4.1 Celgene Company Details
11.4.2 Celgene Business Overview
11.4.3 Celgene Metastatic Cancer Drug Introduction
11.4.4 Celgene Revenue in Metastatic Cancer Drug Business (2017-2022)
11.4.5 Celgene Recent Developments
11.5 AKRON
11.5.1 AKRON Company Details
11.5.2 AKRON Business Overview
11.5.3 AKRON Metastatic Cancer Drug Introduction
11.5.4 AKRON Revenue in Metastatic Cancer Drug Business (2017-2022)
11.5.5 AKRON Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Metastatic Cancer Drug Introduction
11.6.4 Novartis Revenue in Metastatic Cancer Drug Business (2017-2022)
11.6.5 Novartis Recent Developments
11.7 Galen
11.7.1 Galen Company Details
11.7.2 Galen Business Overview
11.7.3 Galen Metastatic Cancer Drug Introduction
11.7.4 Galen Revenue in Metastatic Cancer Drug Business (2017-2022)
11.7.5 Galen Recent Developments
11.8 Pacira BioSciences
11.8.1 Pacira BioSciences Company Details
11.8.2 Pacira BioSciences Business Overview
11.8.3 Pacira BioSciences Metastatic Cancer Drug Introduction
11.8.4 Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2017-2022)
11.8.5 Pacira BioSciences Recent Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Details
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Metastatic Cancer Drug Introduction
11.9.4 Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2017-2022)
11.9.5 Johnson & Johnson Recent Developments
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Details
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Metastatic Cancer Drug Introduction
11.10.4 Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2017-2022)
11.10.5 Fresenius Kabi AG Recent Developments
11.11 Spectrum Pharmaceuticals
11.11.1 Spectrum Pharmaceuticals Company Details
11.11.2 Spectrum Pharmaceuticals Business Overview
11.11.3 Spectrum Pharmaceuticals Metastatic Cancer Drug Introduction
11.11.4 Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2017-2022)
11.11.5 Spectrum Pharmaceuticals Recent Developments
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Details
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Metastatic Cancer Drug Introduction
11.12.4 Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2017-2022)
11.12.5 Takeda Pharmaceutical Recent Developments
11.13 Teva Pharmaceutical Industries
11.13.1 Teva Pharmaceutical Industries Company Details
11.13.2 Teva Pharmaceutical Industries Business Overview
11.13.3 Teva Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.13.4 Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2017-2022)
11.13.5 Teva Pharmaceutical Industries Recent Developments
11.14 Cipla
11.14.1 Cipla Company Details
11.14.2 Cipla Business Overview
11.14.3 Cipla Metastatic Cancer Drug Introduction
11.14.4 Cipla Revenue in Metastatic Cancer Drug Business (2017-2022)
11.14.5 Cipla Recent Developments
11.15 Sun Pharmaceutical Industries
11.15.1 Sun Pharmaceutical Industries Company Details
11.15.2 Sun Pharmaceutical Industries Business Overview
11.15.3 Sun Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.15.4 Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2017-2022)
11.15.5 Sun Pharmaceutical Industries Recent Developments
11.16 Shanghai Fosun Pharmaceutical
11.16.1 Shanghai Fosun Pharmaceutical Company Details
11.16.2 Shanghai Fosun Pharmaceutical Business Overview
11.16.3 Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Introduction
11.16.4 Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2017-2022)
11.16.5 Shanghai Fosun Pharmaceutical Recent Developments
11.17 Ingenus
11.17.1 Ingenus Company Details
11.17.2 Ingenus Business Overview
11.17.3 Ingenus Metastatic Cancer Drug Introduction
11.17.4 Ingenus Revenue in Metastatic Cancer Drug Business (2017-2022)
11.17.5 Ingenus Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の転移性抗がん剤市場インサイト及び予測(トラスツズマブ、ペルツズマブ)(Global Metastatic Cancer Drug Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。